We transform powerful cytokines into life-saving treatments.

Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer Read more

Pipeline

Discovery
Preclinical
Pre-IND
Phase I
Phase II
Partner
ANV419
Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting…
> Read more
Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing…
> Read more
Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and…
> Read more
Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting…
> Read more
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the…
> Read more
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual…
> Read more
Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its…
> Read more
Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO…
> Read more
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress…
> Read more
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual…
> Read more
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in…
> Read more
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology…
> Read more
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting…
> Read more
Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of…
> Read more

About

Meet Our Team

We are a dedicated team of scientists with decades of collective experience in drug development.
Our expertise, curiosity and drive to deliver tangible results set us apart.
We focus on science in order to identify solutions to patient needs.

High-profile investors fund Anaveon

Others share our vision, and international investors have backed Anaveon with funding of more than 146 million CHF (€140 million) since the company’s foundation in 2017.

HCP

Message to Health Care Professionals (HCP)

Anaveon – Message to Health Care Professionals (HCP)

We are exploiting the power of cytokines to orchestrate immune responses by using protein engeneering to create safe and effective treatments for patients with high unmet medical needs.

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept